Tuesday 18 Dec, 2018 09:29 PM
Site map | Locate Us | Login
   Zee Entertainment Enterprises Ltd leads losers in 'A' group    PSU OMCs firm up after crude oil price declines    Beardsell Ltd leads losers in 'B' group    Volumes spurt at Elgi Equipments Ltd counter    IL&FS group shares in demand    REC Ltd jumps 1.51%, up for third straight session    Edelweiss Financial Services Ltd gains for fifth session    Indian Oil Corporation Ltd soars 0.73%, up for fifth straight session    Motherson Sumi Systems Ltd rises for fifth straight session    Oil Country Tubular Ltd leads gainers in 'B' group    Elgi Equipments Ltd leads gainers in 'A' group    Ashoka Buildcon jumps after unit raises funds from Morgan Stanley    Volumes jump at Elgi Equipments Ltd counter    Tata Steel bucks trend after naming new board for thyssenkrupp JV    8K Miles Software Services Ltd Falls 2.74%, S&P BSE IT Sector index Drops 1.1% 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Lupin advances after launching a generic drug in US
13-Mar-18   15:21 Hrs IST

The announcement was made during market hours today, 13 March 2018.

Meanwhile, the S&P BSE Sensex was down 70.97 points or 0.21% at 33,846.97.

On the BSE, 58,000 shares were traded on the counter so far as against the average daily volumes of 1.55 lakh shares in the past one quarter. The stock had hit a high of Rs 784.50 and a low of Rs 766 so far during the day. The stock had hit a 52-week high of Rs 1,498.40 on 23 March 2017 and a 52-week low of Rs 750 on 8 March 2018.

The large-cap company has equity capital of Rs 90.42 crore. Face value per share is Rs 2.

Pharma major Lupin announced the launch of its Tydemy Tablets having received an approval from the United States Food and Drug Administration (USFDA) earlier. The tablets are indicated for use by women to prevent pregnancy and to raise folate levels in women who choose to use an oral contraceptive for contraception. It had annual sales of approximately $22 million in the US as per January 2018 data.

Lupin's consolidated net profit plunged 65% to Rs 221.73 crore on 11.5% decline in net sales to Rs 3900.36 crore in Q3 December 2017 over Q3 December 2016.

Lupin is a transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.G Anand , anand@ssplwealth.com
Hit Count : 9965449
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016  |  MCX : INZ000081736
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 12815 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. Saravana Stocks Pvt. Ltd